血栓塞栓风险和口服抗凝剂在亚临床心房的治疗中
Felix K Wegner1, Lars Eckardt1
1Department of Cardiology II - Electrophysiology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149 Muenster, Germany.
Trends in cardiovascular medicine
|April 12, 2024
概括
连续节律监测设备检测到亚临床心房动 (AF),其血栓栓塞的风险低于临床AF. 目前关于治疗亚临床AF的口服抗凝药的数据显示,风险/益处关系模糊不清,需要对患者进行仔细的选择.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 药理学 药理学是指药理学的学科.
背景情况:
- 持续节律监测设备 (智能手表,植入式循环记录器,起器/除器) 的可用性越来越大.
- 设备检测到的亚临床心房动 (AF) 与通过心电图诊断的临床AF相比,具有较低的血栓塞栓风险.
- 目前的指导方针建议在特定的亚临床AF高风险患者中使用口服抗凝剂,但最近的试验呈现了模糊的风险/益处数据.
研究的目的:
- 审查目前关于口服抗凝剂在亚临床AF中的作用的证据.
- 在临床决策过程中协助关于亚临床AF的抗凝药.
- 确定关于亚临床AF管理的现有证据缺口.
主要方法:
- 对最近的临床试验和指导方针建议的文献综述.
- 对与亚临床AF相关的血栓塞栓风险数据的分析.
- 在亚临床AF中评估口服抗凝剂的风险/益处概况.
主要成果:
- 设备检测到的亚临床AF与临床AF相比,血栓栓塞的风险明显较低.
- 根据最近的试验数据,口服抗凝剂在亚临床AF中的风险/益处关系仍然模两可.
- 关于亚临床AF的最佳抗凝策略,存在证据差距.
结论:
- 由于风险/益处数据模糊,用口服抗凝药治疗亚临床AF需要仔细考虑.
- 需要进一步的研究来澄清口服抗凝剂在预防亚临床AF中发生的血栓栓塞事件中的作用和有效性.
- 个性化风险评估对于指导设备检测的亚临床AF患者的抗凝决定至关重要.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
01:24Disorders of Hemostasis
881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
01:16Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K